ClinicalTrials.gg
Not yet recruitingNCT07717099GUARD-QUANTUMUpdated Jul 21, 2026

Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer

A Phase 2 interventional study of Ra223 and Darolutamide Oral Tablet in Metastatic Hormone-Sensitive Prostate Cance, sponsored by Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD. Not yet recruiting at 12 sites in Spain. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing Radium-223 in Prostatic Neoplasms — 1 open to participants now, 9 under way, 2 of them phase 3. Radium-223 · Prostatic Neoplasms.

Planned enrollment
6th of 17
50 · median 36
Started
2026
the only one that year
Phase 2
11 of 17
1 open now
Registered
17th of 17
by date
Lead sponsor
1 of 17
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Among the 17 studies testing Radium-223 in Prostatic Neoplasms, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 11 in phase 2, and was the 17th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 17 studies testing Radium-223 in Prostatic Neoplasms is open now, in 1 country.

By country, each count listing its studies:

About Radium-223

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing Radium-223 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

GUARD-QUANTUM is a prospective, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study. The rationale behind studying this combination lies in the potential additive or synergistic benefits that may arise from concurrently targeting androgen receptor signaling pathways and bone metastases.

Read the detailed description

The trial will enroll competitively up to 50 patients with mHSPC and high volume disease (i.e. ≥4 bone metastatic foci in Tc-99m bone scanning, with at least one focus located outside the pelvis or vertebral bodies in the spine AND/OR visceral metastasis shown on computed tomography or magnetic resonance imaging not including lymph nodes). Patients should have started and be on treatment as per standard of care with first-line triplet therapy consisting of chemical or surgical androgen deprivation therapy (ADT), docetaxel and darolutamide. At least four cycles of docetaxel should have been administered and the last dosing of docetaxel be \< 12 weeks prior the first planned dose of Ra223. Patients should have a good performance status (ECOG PS 0-2 and Charlson score ≤ 3) and have recovered from any prior toxicity from triplet therapy. Previous treatments other than chemotherapy for locoregional disease are acceptable.

Additionally to the IMPs and AXMPs, the study includes the administration of at least two doses of a bone protecting agent (zoledronic acid or denosumab) is required before the first administration of Ra223, and the bone protecting agent should have been started at least 6 weeks before the first administration of Ra223. Patients should also start treatment with vitamin D and calcium supplements

03

Conditions studied

  • Metastatic Hormone-Sensitive Prostate Cance

Browse trials for

Keywords

  • Ra-223
  • Prostate cancer
  • hormone-sensitive
  • Androgen Pathway Modulation-Sensitive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must fulfill all of the following inclusion criteria to be eligible for enrollment to the study:

  1. Patients must be fully informed about the study and sign the form (ICF) before any study specific assessment.
  2. Patients ≥18 years old.
  3. performance status of 0 to 2 and Charlson score ≤ 3 prior to study entry, after docetaxel.
  4. Patients with or cytologically confirmed diagnosis of prostate adenocarcinoma.
  5. Patients should have received triplet therapy with ADT (luteinizing hormone releasing hormone analogue (LHRHA) for continuous treatment or previous bilateral orchidectomy), docetaxel and darolutamide as therapy for mHSPC. The following conditions apply:

    1. Received ≥ 4 cycles of docetaxel.
    2. Treatment with docetaxel should be finished ≤ 12 weeks before the first planned dose of Ra223.
    3. Having no progression of the disease after triplet therapy completion and before inclusion.

    Note: patients with prior therapies for locoregional disease are acceptable

  6. Patients should have recovered from any prior toxicity from ADT, darolutamide or docetaxel to grade 1 or baseline levels.
  7. Presence of at least 4 bone on the screening bone scan, with or without lymph node and/or visceral metastases.
  8. Asymptomatic or mildly symptomatic (defined as short form question #3 in Brief Pain Inventory worst pain must be \< 4).
  9. Patients should be willing to initiate or continue bisphosphonates /denosumab, calcium and vitamin D supplements (Section 7.4.4) prior to the first dose of Ra223.

    Note: Patients must start treatment with a bone protecting agent (at doses used to reduce the incidence of skeletal related events) before the time of signing the ICF. A minimum of two doses is recommended before the first administration of Ra223. The first administration of Ra223 should be scheduled at least 6 weeks after the first administration of the bone protecting agent.

  10. T-score ≥ -2.5 on a DXA scan done in the past 12 months. A DXA scan performed during the screening period will be encouraged but not mandated.
  11. Adequate organ and bone marrow function as follows (subject must not have received any growth factor within 4 weeks or a blood transfusion within 7 days of the hematology laboratory):

    1. (ANC) ≥ 1.5 x109/L;
    2. ≥ 100 x109/L;
    3. ≥ 9.0 g/dl;
    4. Total level ≤ 1.5 x institutional (ULN), except for patients with Gilbert's disease ≤ 5.0 x ULN;
    5. (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN;
    6. Creatinine ≤ 1.5 x ULN;
    7. \< 30 mL/min;
    8. Albumin > 25 g/L.
  12. Participants who have pregnant partners must use a condom and those with partners of must use a condom and another adequate measure if engaging in sexual activities during the study treatment period and for at least 1 week after last dose of darolutamide and 6 months after the last dose of Ra223. A highly effective method of birth control is defined as those which result in low failure rate (i.e., less than 1% per year) when used consistently and correctly.

Exclusion criteria

EXCLUSION CRITERIA:

Subjects with any of the following could not enroll in this study:

  1. Presence of tumor lesion in central nervous system through radiologically confirmed diagnosis.
  2. Prior history of other than prostate adenocarcinoma (except patients with basal cell, squamous cell carcinoma of the skin, in-situ carcinoma or low-grade superficial bladder cancer, or the patient has been free of malignancy for a period of 3 years prior to inclusion).
  3. Patients experiencing progression during previous ADT or meeting criteria for castration resistant prostate cancer (CRPC).

    Note: Prior ADT is allowed.

  4. External irradiation, brachytherapy, or local treatment (including radiofrequency ablation, cryotherapy, high intensity focused ultrasound, etc.) within 4 weeks prior to the first dose of study treatment.
  5. Received prior chemotherapy for prostate cancer other than as part of triplet therapy for mHSPC.
  6. Major surgery within 4 weeks prior to treatment.
  7. Prior hemibody external radiotherapy.
  8. are allowed only at a dose ≤ 10 mg of prednisone (or equivalent) no matter the indication.
  9. Receiving abiraterone treatment as part of the first-line triplet therapy for mHSPC.

    Note: An increased risk of death and fractures was observed in a clinical study in which Ra223 was added to abiraterone acetate and prednisone/prednisolone in patients with asymptomatic or mildly symptomatic CRPC and this is the rationale to not include patients with this combination.

  10. Plan to receive any other antitumor therapies during this trial.
  11. Treatment with an drug within the previous 4 weeks, or planned during the treatment period.
  12. Any other serious illness or medical condition such as, but not limited to:

    1. Any uncontrolled infection ≥ Grade 2 according to v6.0;
    2. Gastrointestinal disorder affecting absorption (e.g., gastrectomy or active peptic ulcer disease);
    3. Crohn's disease or ulcerative colitis;
    4. Osteonecrosis of the jaw;
    5. Non-malignant bone disease with an osteoblastic activity;
    6. Bone marrow dysplasia;
    7. Fecal incontinence;
    8. Life-threatening illness unrelated to cancer.
  13. Significant cardiovascular disease including:

    1. Uncontrolled angina within 3 months prior to screening;
    2. Congestive heart failure (NYHA) class III or IV, or patients with history of congestive heart failure NYHA class III or IV in the past, unless a screening echocardiogram or multi-gated acquisition scan () performed within 3 months results in a left ventricular ejection fraction that is ≥ 45%. Of note, MUGA scans at baseline will not be mandated.
    3. History of ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes);
    4. History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place;
    5. Uncontrolled hypertension as indicated by a resting systolic blood pressure > 160 millimeters of mercury (mm Hg) or diastolic blood pressure > 100 mm Hg at screening; Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to inclusion. Blood pressure must be re-assessed on two occasions that are separated by a minimum of 1 hour. The mean SBP / DBP values from each blood pressure assessment must be ≤ 160/100 mm Hg in order for a patient to be eligible for the study.
  14. Known to any of the study drugs, study drug classes, or in the formulation of the study drugs. No known hypersensitivity to Ra223 (refer to summary of product characteristics [SmPC]).
  15. to both CT and MRI contrast agents.
  16. Contraindications for the use of bisphosphonates or denosumab as per physician judgment.
  17. Involvement in another therapeutic trial involving an experimental drug.
  18. Drug or alcohol abuse.
  19. Any medical condition that in the opinion of the investigator will negatively affect patients' clinical status when participating in this trial.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    QUANTUM intervention

    Six intravenous administrations of Radium-223 chloride, in a dose of 55 kBq/kg body weight standard dose with a treatment interval between administrations of 4 weeks. Treatment with Ra223 could be prematurely discontinued in case of progression, unacceptable toxicity, withdrawal or death. Patients received backgrount therapy with ADT and darolutamide

    Drug: Ra223 · Drug: Darolutamide Oral Tablet · Other: Androgen Deprivation Therapy (ADT)

Interventions

  • DrugRadium-223Studies of Radium-223Radium-223 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Six intravenous administrations of Radium-223 chloride, in a dose of 55 kBq/kg body weight standard dose with a treatment interval between administrations of 4 weeks. Treatment with Ra223 could be prematurely discontinued in case of progression, unacceptable toxicity, withdrawal or death.

  • DrugDarolutamideStudies of DarolutamideDarolutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Darolutamide at 600 mg twice daily. Darolutamide administration will continue until progression, unacceptable toxicity, withdrawal or death, whichever comes first.

  • OtherAndrogen Deprivation Therapy (ADT)

    Standard of care ADT (surgical or drug). Administration will continue until progression, unacceptable toxicity, withdrawal or death, whichever comes first.

06

What researchers measure

Primary outcomes

  1. Treatment compliance

    Measured as the total number of cycles administered to each patient. Patients will be categorized in two groups, complete treatment compliance (complete ≥5 cycles of Ra223) and incomplete treatment compliance (complete \<5 cycles of Ra223). The proportion of patients in each category and their 95% confidence interval (CI) calculated by Clopper-Pearson will be given.

    Time frame: Throughout the study treatment period, approximately 6 months

Secondary outcomes

  1. Prostate-specific antigen (PSA) response rates

    Response is defined as PSA \<0.02 ng/mL at Ra223 completion. Rate of PSA response is defined as the number of subjects with absolute PSA response, divided by the total number of subjects evaluable for absolute PSA response (with high PSA levels at baseline).

    Time frame: Throughout the study period, approximately 18 months

  2. Total alkaline phosphatase response rates

    Defined as a reduction of ≥30% from the baseline value, before the first dose of study treatment (Ra223). The ALP response will be assessed only in patients with ALP increased levels at baseline. Percentage of patients who experience these reductions throughout the study period.

    Time frame: Throughout the study period, approximately 18 months

  3. Radiographic progression-free survival (rPFS)

    Defined from the day of first dose of Ra223 to the day the first event of radiological progression or death (due to any cause) is recorded. Assessed by investigator and defined as motivated by the recommendations of the Prostate Cancer Clinical Trials Working Group 3for the "delay/prevent" objective. rPFS will be estimated by Kaplan-Meier method. Patients who are alive without evidence of radiological progression at their last imaging assessment will be censored at that date.

    Time frame: Throughout the study period, approximately 18 months

  4. Time to pain progression

    Measured according to Brief Pain Inventory (BPI). Pain progression is defined in patients in the 'pain evaluable' population as: an increase of 2 or more points in the BPI's "worst pain in 24 hours"-score from baseline observed at 2 consecutive evaluations ≥4 weeks apart, or initiation of short or long-acting opioid use for pain. Time-to-pain progression is defined as the time (days) from the first dose of study treatment (Ra223) date, to the date of pain progression

    Time frame: Throughout the study period, approximately 18 months

  5. Time to next systemic antineoplastic therapy

    This is the interval of time between first dose of study treatment (Ra223) and the first day of initiation of a next line of systemic antineoplastic therapy after the initial scheduled treatment.

    Time frame: Throughout study period, approximately 18 months

  6. Time to castration resistance

    Defined as the time to PSA progression (according to PCWG3 criteria is defined as the date that a 25% or greater increase and absolute increase of 2 ng/mL or more from the nadir \[lowest at or after baseline\] is documented, which both are confirmed by a second value obtained at least 3 weeks later, including all potential PSA values ≥2 ng/mL above nadir and ≥25% increase above nadir between initial assessment date and confirmation assessment date) with serum testosterone being at castrate level \<0.50 ng/mL, or the time to progression by soft tissue lesions or bone lesions (as described above), whatever comes first.

    Time frame: Throughout the study period, approximately 18 months

  7. Overall survival (OS)

    Measured from the date of first dose of study treatment (Ra223) to the date of death whatever the cause of death. OS will be estimated by Kaplan-Meier method. Patients who are alive are censored at the date of the most recent follow-up examination.

    Time frame: Throughout the study period, approximately 18 months

  8. Time to symptomatic skeletal event

    Defined as the time elapsed between the day of first dose of study treatment administration (Ra223) to the day of symptomatic skeletal event recorded for each patient. Symptomatic Skeletal-related events (SSEs) are defined as the first event of: the first use of external-beam radiation therapy to relieve skeletal symptoms, new symptomatic pathologic vertebral or non-vertebral bone fractures, spinal cord compression, or tumor-related orthopedic surgical intervention.

    Time frame: Throughout the study period, approximately 18 months

  9. Incidence of dose interruption

    Percentage of patients experiencing dose interruptions

    Time frame: Throughout the study treatment period, approximately 6 months

  10. Health-related quality of life (HRQoL) through EQ-5D-5L

    The EQ-5D-5L is a standardized, widely used questionnaire designed to measure a person's HRQoL. It evaluates overall health across five distinct dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and provides an actionable index score and a visual assessment of health status. Here we will report the total score: The top of the scale (100) represents "The best health you can imagine". The bottom of the scale (0) represents "The worst health you can imagine"

    Time frame: Throughout the study period, approximately 18 months

  11. Health-related quality of life (HRQoL) through National Comprehensive Cancer Network Functional Assessment of Cancer Therapy - Prostate (FACT-P)

    The FACT-P is a validated, multidimensional, patient-reported questionnaire used to evaluate the HRQOL of men diagnosed with prostate cancer. It is widely used by clinicians and researchers to track physical, emotional, and social well-being over time. The assessment consists of 39 questions/statements graded on a 5-point Likert scale (ranging from 0 = "not at all" to 4 = "very much"). It is divided into five core domain: physical, social, emotional, functional and prostatic. Here we will report the total score. The total FACT-P score ranges from 0 to 156. Higher scores represent a better health-related quality of life.

    Time frame: Throughout the study period, approximately 18 months

Other outcomes

  1. Assessment of disease volume by novel imaging modalities (Prostate-Specific Membrane Antigen Positron Emission Tomography [PET-PSMA])

    Patients will be assessed through PT-PSMA. The volume of disease will be reported trhough time. Best tumor size reduction will be reported

    Time frame: Throughout the study period, approximately 18 months

  2. Biomarkers

    Transcriptome and whole genome sequencing to identify biomarkers that correlate with prognosis. Here we will report the most frequent genetic alterations and their prevalence in the study population. The analysis will be done in tumor and blood samples.

    Time frame: Tumor archival tissue sample at baseline. Blood samples at baseline, within 7 days before end of Cycle 3 (each cycle is 28 days) and at disease progression

07

Study locations

12 sites
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Santa Creu i Sant Pau
    Barcelona, 08041, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Complejo Hospitalario Universitario Materno-Infantil de Gran Canaria (CHUIMI)
    Las Palmas de Gran Canaria, 35016, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Responsible Person Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario Central de Asturias (HUCA)
    Oviedo, 33011, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Complejo Hospitalario Universitario de Santiago (CHUS)
    Santiago de Compostela, 15706, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
  • Instituto Valenciano de Oncología (IVO)
    Valencia, 46009, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator designed by the Sponsor, M.D., Ph.D. · Principal investigator
  • Hospital Clínico Universitario de Valladolid (HCUV)
    Valladolid, 47003, Spain
    • A responsible person Designated by the Sponsor · Contactinvestigacion@mfar.net · 0034934344412
    • A Principal Investigator Designated by the Sponsor, M.D., Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2029, 39 months later.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 39 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 21, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2029
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07717099
Lead sponsor
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Collaborators
Bayer, MFAR
Responsible party
Sponsor
First posted
Jul 21, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Jul 21, 2026

Study contacts

GUARD Secretary
Contact
info@guardconsortium.org
0034933931838
David Lorente, M.D., Ph.D.
study chair · Instituto Valenciano de Oncología
Guillermo de Velasco, M.D., Ph.D.
study chair · Hospital Universitario 12 de Octubre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Radium-223

Start the discussion